All In Biotech

Drug Trial Radar · NCT06344936

Drug-drug Interaction Study of HRS-1780 Tablets in Healthy Subjects

Open-Label Assessment of the Effects of Itraconazole and Rifampicin on HRS-1780 Pharmacokinetics in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Apr 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

28

Planned (sponsor's estimate)

Start

Apr 2024

Primary completion

Jul 2024

Study completion Jul 2024

Sponsor

Sponsor type
Industry
First posted
Apr 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study was designed to evaluate the pharmacokinetic effects of itraconazole and rifampicin on HRS-1780 after oral administration of HRS-1780 tablets in healthy subjects

Conditions

  • Chronic Kidney Disease(CKD)

Interventions

  • HRS-1780 tablets; Itraconazole capsules; Rifampicin capsulesDrug

    Treatment PartⅠ: Itraconazole capsule, 200mg QD, 7 times; HRS-1780 tablets, 10mg QD, twice Treatment PartⅡ: Rifampicin capsules, 600mg QD, 14 times; HRS-1780 tablets, 10mg QD, twice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess the Cmax of HRS-1780 in plasma.Time frame: About 3 days after the dose.
  2. Assess the Tmax of HRS-1780 in plasma.Time frame: About 3 days after the dose.
  3. Assess the t1/2 of HRS-1780 in plasma.Time frame: About 3 days after the dose.
  4. Assess the AUC0-t of HRS-1780 in plasma.Time frame: About 3 days after the dose.
  5. Assess the AUC0-inf of HRS-1780 in plasma.Time frame: About 3 days after the dose.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.